Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Calcifediol in Chronic Renal Insufficiency-Reply

Calcifediol in Chronic Renal Insufficiency-Reply We appreciate the comments of Drs Coburn and Norman, particularly as regards the hypercalcemic potential of any analogue of vitamin D, illustrating the great care necessitated in using these compounds. We also concur that the superiority (if any) of one natural or synthetic analogue is yet to be proved, although there are little data in the report from Drs Coburn and Norman's group that 1,25-dihydroxycholecalciferol is effective in reversing the osteomalacic manifestations of uremic bone.1 Drs Coburn and Norman, however, have missed the point of our report, which is to demonstrate the effectiveness of a vitamin D metabolite prior to 1-hydroxylation in the treatment of uremic osteodystrophy. In this regard, we take issue with the contention that interest in the use of vitamin D analogues in uremia center on bypassing "the necessity for 1-hydroxylation in the kidney." Experimental observations of beneficial effect on the uremic skeleton2 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Calcifediol in Chronic Renal Insufficiency-Reply

JAMA , Volume 236 (4) – Jul 26, 1976

Calcifediol in Chronic Renal Insufficiency-Reply

Abstract


We appreciate the comments of Drs Coburn and Norman, particularly as regards the hypercalcemic potential of any analogue of vitamin D, illustrating the great care necessitated in using these compounds. We also concur that the superiority (if any) of one natural or synthetic analogue is yet to be proved, although there are little data in the report from Drs Coburn and Norman's group that 1,25-dihydroxycholecalciferol is effective in reversing the osteomalacic manifestations of uremic...
Loading next page...
 
/lp/american-medical-association/calcifediol-in-chronic-renal-insufficiency-reply-W4Hv92ihu7

References (2)

Publisher
American Medical Association
Copyright
Copyright © 1976 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1976.03270040013016
Publisher site
See Article on Publisher Site

Abstract

We appreciate the comments of Drs Coburn and Norman, particularly as regards the hypercalcemic potential of any analogue of vitamin D, illustrating the great care necessitated in using these compounds. We also concur that the superiority (if any) of one natural or synthetic analogue is yet to be proved, although there are little data in the report from Drs Coburn and Norman's group that 1,25-dihydroxycholecalciferol is effective in reversing the osteomalacic manifestations of uremic bone.1 Drs Coburn and Norman, however, have missed the point of our report, which is to demonstrate the effectiveness of a vitamin D metabolite prior to 1-hydroxylation in the treatment of uremic osteodystrophy. In this regard, we take issue with the contention that interest in the use of vitamin D analogues in uremia center on bypassing "the necessity for 1-hydroxylation in the kidney." Experimental observations of beneficial effect on the uremic skeleton2

Journal

JAMAAmerican Medical Association

Published: Jul 26, 1976

There are no references for this article.